ISRCTN89404187
Completed
Phase 4
A prospective, multi-center, post-market surveillance study to assess the clinical efficacy and fusion rates of the Zimmer®TM Ardis Interbody Fusion System
Zimmer Spine (France)0 sites80 target enrollmentJanuary 27, 2014
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Zimmer Spine (France)
- Enrollment
- 80
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age 18 years or over
- •2\. Degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies.
- •3\. ODI over or equal to 40/100
- •4\. Back pain over or equal to 4/10
- •5\. Mono segmental lumbosacral disease fulfilling the prior conditions: only one level between L2 and S1
- •6\. Skeletally mature patients
- •7\. Six months failed conservative treatment
- •8\. Gave written consent to take part in the study by signing patient informed consent form
- •9\. Physically and mentally able to comply with the protocol, including ability to read and complete required forms and adhere to the follow\-up requirements of the protocol
Exclusion Criteria
- •1\. Prior surgical procedure at the index level using the desired operative approach
- •2\. Severe degenerative lesions at more than one level of the lumbosacral spine
- •3\. Morbid obesity (BMI \= 40\)
- •4\. Active local infection in or near the operative region
- •5\. Active systemic infection and/or disease
- •6\. Severe osteoporosis or insufficient bone density, which in the medical opinion of the physician precludes surgery or contraindicates instrumentation
- •7\. Known or suspected sensitivity to the implant materials
- •8\. Endocrine or metabolic disorders known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, hypothyroidism)
- •9\. Systemic disease that requires the chronic administration of nonsteroidal anti\-inflammatory or steroidal drugs
- •10\. Significant mental disorder or condition that could compromise the patient's ability to remember and comply with preoperative and postoperative instructions (e.g. current treatment for a psychiatric/psychosocial disorder, senile dementia, Alzheimer's disease, traumatic head injury)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
ational, multicentre post market surveillance study on anterior pelvic prolapse reconstruction with a titanium-coated polypropylene mesh (TiLOOP® PRO A)N81N81.1Female genital prolapseCystoceleDRKS00010001pfm medical ag54
Completed
Phase 4
Superia: Sirolimus Eluting Coronary Stent System (SSECSS) India Post Marketing RegistryCTRI/2012/01/002393Innvolution Med System200
Active, not recruiting
Phase 1
Post marketing surveillance to collect safety information after vaccination with Bexsero administered in routine care and according to prescribing information in Korea.The study will collect real-world post-vaccination adverse events.EUCTR2023-000765-14-Outside-EU/EEAGlaxoSmithKline Biologicals SA
Not yet recruiting
Phase 4
Post marketing surveillance of Aripiprazole tabletHealth Condition 1: F209- Schizophrenia, unspecifiedCTRI/2022/01/039860Torrent Pharmaceuticals Limited
Active, not recruiting
Phase 4
A post marketing study to monitor safety of Abiraterone Acetate (Zytiga) in Indian patients with Prostate CancerHealth Condition 1: null- Indian participants with metastatic, castration-resistant prostate cancer will be enrolled in this study.CTRI/2016/04/006854Johnson Johnson Private Limited